{"id":791455,"date":"2024-12-02T08:03:15","date_gmt":"2024-12-02T13:03:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/"},"modified":"2024-12-02T08:03:15","modified_gmt":"2024-12-02T13:03:15","slug":"aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/","title":{"rendered":"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }\n.bwlistsquare { list-style-type: square }\n.bwpadb3 { padding-bottom: 4px }\n.bwpadl0 { padding-left: 0px }\n.bwpadr0 { padding-right: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwuline { text-decoration: underline }\n.bwvertalignt { vertical-align: top }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board<\/b><\/p>\n<p class=\"bwalignc\"><i>Highlights Activist Group\u2019s Nominees\u2019 Checkered Backgrounds, Skewed Incentives and Lack of Independence<\/i><\/p>\n<p class=\"bwalignc\"><i>Warns AIM Shareholders of Activist Group\u2019s Plan to Reimburse Individuals More Than $5 Million for Failed Litigation Against AIM, in Addition to Any Expenses Incurred in Connection With This Year\u2019s Proxy Contest<\/i><\/p>\n<p class=\"bwalignc\"><i>Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates and Discarding Any Proxy Materials Received from the Activist Group<\/i><\/p>\n<p>OCALA, Fla.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d) today issued a presentation highlighting why shareholders should NOT elect the four director candidates nominated by a group of activist investors (collectively, the \u201cActivist Group\u201d) as part of their multi-year attempt to take over AIM\u2019s Board of Directors (the \u201cBoard\u201d) at the upcoming 2024 Annual Meeting of Stockholders (the \u201cAnnual Meeting\u201d), presently scheduled for December 17, 2024.<\/p>\n<p>\nView the full presentation <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmunotech.s3.us-west-1.amazonaws.com%2FThe%2BActivist%2BGroup%25E2%2580%2599s%2BSlate%2Bis%2Bthe%2BWrong%2BChoice%2Bfor%2BAIM%2BShareholders%2B%28December%2B2024%29.pdf&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=5557498a8c96fa5f678bb398e8de7ea8\">here<\/a>. Highlights include:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b><span class=\"bwuline\">Robert Chioini \u2013 Activist Group Nominee and Interim CEO Candidate\n<p><\/span><\/b><\/p>\n<ul class=\"bwlistcircle\">\n<li>\nFired as CEO of Rockwell Medical in 2018 because of his \u201c<b>sustained mismanagement<\/b>\u201d of the company and \u201c<b>blatant disregard for shareholder concerns<\/b>,\u201d according to a Rockwell Medical spokesperson.<sup>1<\/p>\n<p><\/sup><\/li>\n<li>\nFollowing his termination, Mr. Chioini<i \/>\u201c<b>refuse[d] to accept the decision<\/b>\u201d and, without authorization, filed a Current Report on Form 8-K on the company\u2019s behalf \u201c<b>making various assertions regarding the five independent directors who voted in favor of Mr. Chioini\u2019s removal<\/b><i>.<\/i>\u201d<sup>2<\/p>\n<p><\/sup><\/li>\n<li>\nHas agreed to have AIM shareholders <b>repay him and other individuals more than $5 million in litigation expenses for a failed Board takeover attempt in 2023<\/b>, in addition to any costs incurred in connection with the attempt to take over the Board at this year\u2019s Annual Meeting \u2013 <b>without letting shareholders vote directly on this reimbursement.<\/b><sup>3<\/p>\n<p><\/sup><\/li>\n<li>\nMr. Chioini was <b>part of the group that orchestrated the 2022 campaign to take over the AIM Board and planned this with two convicted criminals<\/b> \u2013 Franz Tudor and Michael Xirinachs \u2013 <b>despite owning no AIM stock<\/b>.<sup>4<\/p>\n<p><\/sup><\/li>\n<li>\nHe <b>sought to hide the involvement of these criminals <\/b>and recruited another individual, Jonathan Jorgl, to be the \u201cface\u201d of the effort.<sup>5<\/p>\n<p><\/sup><\/li>\n<li><b>This history of poor judgment and unacceptable behavior indicates, in the Board\u2019s view, that Mr. Chioini is unfit to serve as a public company director \u2013 let alone CEO.<\/b><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b><span class=\"bwuline\">Todd Deutsch \u2013 Activist Group Nominee\n<p><\/span><\/b><\/p>\n<ul class=\"bwlistcircle\">\n<li>\nWorked with Mr. Tudor, a prior member of the Activist Group, at the Galleon Group, a hedge fund at the center of an insider trading scandal in 2009 that led to over 50 convictions or guilty pleas \u2013 including <b>Mr. Tudor, who pled guilty to conspiracy to commit securities fraud<\/b>.<sup>6<\/p>\n<p><\/sup><\/li>\n<li>\nMaintained a relationship with Mr. Tudor despite Mr. Tudor\u2019s questionable history.<\/p>\n<ul class=\"bwlistsquare\">\n<li>\nThe Delaware Court of Chancery (the \u201cCourt\u201d) noted in December 2023 that \u201c<b>[Mr.] Tudor is now employed by [Mr.] Deutsch to do \u2018back office\u2019 tasks<\/b>.\u201d<sup>7<\/p>\n<p><\/sup><\/li>\n<\/ul>\n<\/li>\n<li>\nHas agreed to have AIM shareholders <b>repay him and other individuals more than $5 million in litigation expenses for a failed Board takeover attempt in 2023<\/b>, in addition to any costs incurred in connection with their attempt to take over the Board at this year\u2019s Annual Meeting \u2013 <b>without letting shareholders vote directly on this reimbursement.<\/p>\n<p><\/b><\/li>\n<li><b>The Board believes that Mr. Deutsch\u2019s checkered past in relation to Galleon Group, as well as the fact that he as recently as last year employed a convicted securities law felon, should give shareholders pause about his judgment and commitment to protecting their best interests.<br \/>\n<br \/><\/b><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b><span class=\"bwuline\">Ted Kellner \u2013 Activist Group Nominee and Leader of 2023 and 2024 Board Takeover Attempts\n<p><\/span><\/b><\/p>\n<ul class=\"bwlistcircle\">\n<li><b>Led a group for the second year in a row that is closely associated with securities law felons \u2013 in an effort to take control of the Board.\n<p><\/b><\/li>\n<li><b>Has insisted that AIM pay him and other individuals a premium of more than $8 million to settle this proxy contest.\n<p><\/b><\/li>\n<li><b>Realized he might be associating with a felon convicted of insider trading \u2013 yet proceeded anyway.<\/b>\n<ul class=\"bwlistsquare\">\n<li>\nThe Court\u2019s discovery found on \u201c<i>handwritten notes on a copy of the letter, Kellner wrote \u2018FRANZ TUDOR \u2013 IS A FELON?\u2019 and \u2018INSIDER TRADING?\u2019<\/i>\u201d<sup>8<\/p>\n<p><\/sup><\/li>\n<\/ul>\n<\/li>\n<li>\nWas found to have <b>lied to shareholders <\/b>by the Court.<\/p>\n<ul class=\"bwlistsquare\">\n<li>\nIn relation to the 2023 nomination notice, the Court noted, \u201c<i>Directors and stockholders would justifiably want to know whether a nomination is part of a broader scheme. <b>Such information was withheld from or obfuscated<\/b><b>in the Kellner Notice<\/b>.<\/i>\u201d<sup>9<\/p>\n<p><\/sup><\/li>\n<li>\nThe Court added, \u201c<i>The Kellner Notice states that before July 2023, \u2018no decision was made [for any of Kellner, Deutsch or Chioini] to work together to advance potential nominations or otherwise take any action with respect to the Company.\u2019 <b>This statement is false<\/b>.<\/i>\u201d<sup>10<\/p>\n<p><\/sup><\/li>\n<\/ul>\n<\/li>\n<li>\nAdditionally, the Delaware Supreme Court wrote the following: <i>\u201cWe also note that, according to the Court of Chancery, <b>Kellner submitted false and misleading responses<\/b> to some of the requests\u201d<\/i> and referenced <i>\u201cKellner\u2019s and his nominees\u2019 <b>deceptive conduct.<\/b>\u201d<\/i><sup>11<\/p>\n<p><\/sup><\/li>\n<li>\nHas agreed to have AIM shareholders <b>repay him and other individuals more than $5 million in litigation expenses for a failed Board takeover attempt in 2023<\/b>, in addition to any costs incurred in connection with their attempt to take over the Board at this year&#8217;s Annual Meeting \u2013 <b>without letting shareholders vote directly on this reimbursement.<\/p>\n<p><\/b><\/li>\n<li><b>Mr. Kellner has lied to AIM shareholders, is trying to get control of the Board and intends to take more than $5 million out of the Company for reimbursement in connection with the failed Board takeover attempt in 2023 alone. The Board believes that his election to the Board would not be in the best interests of all shareholders.<\/b><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b><span class=\"bwuline\">Paul Sweeney \u2013 Activist Group Nominee\n<p><\/span><\/b><\/p>\n<ul class=\"bwlistcircle\">\n<li>\nNot independent of the Activist Group \u2013 has a <b>long-standing personal and business relationship with Mr. Kellner, <\/b>with whom he invested together in numerous other private businesses and ventures. In certain cases, they have done so through special purpose vehicles in which one or both of them have served as managers, as was the case with Coyote Fund, LLC, FM Qualified Opportunity Fund LLC, TK-Karma Investment, LLC and DTP3, LLC1.<sup>12<\/p>\n<p><\/sup><\/li>\n<li>\nReceived an aggregate of over <b>$15.0 million in funds from Mr. Kellner<\/b> for 13 active investments sponsored by PS Capital Partners, a private equity firm of which Mr. Sweeney is co-founder and a principal. In fact, Mr. Kellner is quoted on PS Capital Partners\u2019 website saying: <i>\u201cI have never missed an opportunity to invest with PS Capital and am happy to be the largest investor in almost every deal.\u201d<\/i><sup>13<br \/>\n<i><b><\/p>\n<p><\/b><\/i><\/sup><\/li>\n<li><b>Invested extensively within Fiduciary Real Estate Development, Inc., a business founded by Mr. Kellner<\/b>, including<b> ~$150,000 personally<\/b> and <b>~$375,000<\/b> through PS Capital Partners.<sup>14\n<p><\/sup><\/li>\n<li><b>Serves with Mr. Kellner as a member of a number of clubs and organizations, including <\/b>Milwaukee Athletic Club, Greater Milwaukee Committee, Milwaukee World Festival, MMAC and Children\u2019s Wisconsin.\n<\/li>\n<li><b>Lacks any relevant board or senior management experience in the biotech industry.\n<p><\/b><\/li>\n<li>\nHas shown <b>poor judgment<\/b>, in the Board\u2019s view,<b \/>in getting involved with the Activist Group.<\/p>\n<\/li>\n<li><b>The Board questions how Mr. Sweeney can act independently as a member of the AIM Board given his extensive ongoing business and investment relationship with Mr. Kellner, which, in the Board\u2019s view, would make him highly likely to simply agree with Mr. Kellner\u2019s positions rather than considering the best interests of all shareholders.<\/b><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\nThe Activist Group nominees have not proposed a compelling plan for AIM and appear to be focused on seeking reimbursement for their past expenses.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTo settle, the Activist Group is demanding <b>upwards of $8 million in litigation expenses <\/b>from AIM for money its members spent on failed lawsuits against the Company.<\/p>\n<\/li>\n<li>\nIf the Activist Group\u2019s nominees are elected to the Board, they have blatantly stated in their definitive proxy statement: \u201cIn addition to the foregoing amount, each of Mr. Kellner, Mr. Deutsch and Mr. Chioini <b>intend to seek reimbursement from the Company of all expenses they incurred in connection with their solicitation for the 2023 Annual Meeting (including related litigation expenses), which amounts to approximately $5.3 [million]\u2026 and they do not intend to submit the question of such reimbursement to a vote of security holders of the Company.<\/b>\u201d<\/p>\n<\/li>\n<\/ul>\n<p class=\"bwalignc\"><b>The Activist Group Slate is the <span class=\"bwuline\">WRONG<\/span> Choice for AIM Shareholders.<\/b><\/p>\n<p class=\"bwalignc\">\n***<\/p>\n<p>\nAIM encourages shareholders to vote \u201c<b>FOR<\/b>\u201d ALL four of the Board\u2019s incumbent candidates \u2013 <b>Stewart L. Appelrouth<\/b>, <b>Nancy K. Bryan<\/b>, <b>Thomas K. Equels<\/b> and <b>Dr. William M. Mitchell<\/b> \u2013 in connection with the Annual Meeting, on the <b><span class=\"bwuline\">WHITE<\/span><\/b> universal proxy card.<\/p>\n<p>\nFor more information on how to vote, visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SafeguardAIM.com&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=www.SafeguardAIM.com&amp;index=2&amp;md5=6a4d04986331ab46c672bb0372e8933b\">www.SafeguardAIM.com<\/a>.<\/p>\n<p class=\"bwalignc\">\n***<\/p>\n<p><b>About AIM ImmunoTech Inc.<\/b><\/p>\n<p>\nAIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company\u2019s lead product is a first-in-class investigational drug called Ampligen<sup>\u00ae<\/sup> (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.<\/p>\n<p>\nFor more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DNJE1OVmM3vXX32UkYGXxM6a6gkfQ_2DnYLGx5Klimcg0SIUEXl6aHRMSXtvH1CLTDWpH3rTZCiAufpi5t6p-9p0EjO4NkMNsbEmaTpDEswzNvszJH-aM8EOVRVV888nSbRAC2vgyABZdN43GQxbKWBWzq50NJCOKM_txPvOidUGSpZiA6wkCZ9XafYPMf374-f3xMdS5d6mvfaEOh-SJLIKjWpDnDC4MU6UbdbumhiM%3D&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=aimimmuno.com&amp;index=3&amp;md5=8d4e99567c295d80461a514b7f123a72\">aimimmuno.com<\/a> and connect with the Company on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D92BdXKffHdlioqhz-03Fs1SCxSuJ_YoMC7zzeRUzUmKpf7AaDkBpYBTNmSb7rglz-sAOfhSiDQnjcDs7oVHDxRh8XwYe4c-pmYVskUuuh8bvCHDBFGX4xLNz1zK4hU7V6GLIwLCNHTpTc3UrFO1v2vYwW81LULNmHnyAioz-3x4z48aJsAJoIQ8tFBHNuatL8y9ibmHX8n4XrDgC1-b7mA%3D%3D&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=962c006da616dfa47bbf692a23f9a67a\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DsH78EHx_UKrXcfI2LUu9Z-lJSSOS6QZWbFZ_oXe2paNrGUii0hZrZS-O8LpzT9xas82flUWriJU1CELIbJRK3auVrVaEDkTliYmOtiiS1roLBVcUKuFc-VDV3F9CDOzZtpr5OP-EhbFK6rWaduz5-fjevnRRIXmlvFUqnlpPBQjjsV2btrpz-PCrlg5pZboGQ-kTvRf26jHEl590OiKDSQJFO18V8Jv64H91CHtkRYqC2k-setqZttauwo7FW8mY&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=9fc3b8a3518e85c28c866b62bafc6cec\">LinkedIn<\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DJeXN46_2i1JvodZ_6kBxk9GunKEzpFGqa2Zmmrlzfr4Raz091cyw-p8SHz23j3lH6K5xQJYu-rKrBzzt7EpdtatCcPFQhMr5aS_RpmlQP2HbCicT2yIIM0Ye7C_X2GrDyMo2HtaxnWuXkNHO4tixq669IbfdjHIGzxPmlgv2n2HYlb4VgXnlnYvcMdFgr2LS-P21zmT51kPJv3oeCw7PI4dx2Oaf5iH_8SeuZPb3MuZi95OBx6XpmsSUQjgSPirK&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=994638da8096e05e3f1aaa1b9fe1202b\">Facebook<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the \u201cPSLRA\u201d). Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccontinue,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201cupcoming\u201d and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date does not guarantee that Ampligen will be approved as a treatment or therapy for any diseases or conditions. The Company urges investors to consider specifically the various risk factors identified in its most recent Annual Report on Form 10-K, and any risk factors or cautionary statements included in any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.<\/p>\n<p><b>Important Additional Information<\/b><\/p>\n<p>\nThe Company, its directors and executive officers, Peter W. Rodino, III and Robert Dickey, IV, are deemed to be \u201cparticipants\u201d (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company\u2019s stockholders in connection with the Annual Meeting. The Company filed its definitive proxy statement (the \u201cDefinitive Proxy Statement\u201d) and a <b>WHITE <\/b>universal proxy card with the SEC on November 4, 2024 in connection with such solicitation of proxies from the Company\u2019s stockholders. <b>STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT, ACCOMPANYING WHITE UNIVERSAL PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING.<\/b> The Definitive Proxy Statement contains information regarding the identity of the participants, and their direct and indirect interests, by security holdings or otherwise, in the Company\u2019s securities and can be found in the section titled \u201cPrincipal Stockholders\u201d of the Definitive Proxy Statement and available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F946644%2F000149315224043423%2Fformdefc14a.htm%23%3A%7E%3Atext%3Dour%2520common%2520stock.-%2CPRINCIPAL%2520STOCKHOLDERS%2C-The%2520following%2520table&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=here&amp;index=7&amp;md5=240e136d3dfa060352223f1b31f8ed01\">here<\/a>. Information regarding subsequent changes to their holdings of the Company\u2019s securities can be found in the SEC filings on Forms 3, 4, and 5, which are available on the Company\u2019s website available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=here&amp;index=8&amp;md5=1ed2090383a1b6ede7a3b55be5e6b3c4\">here<\/a> or through the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=477f396ad63ddf36fbe8c9f473709eed\">www.sec.gov<\/a>. Stockholders will be able to obtain the Definitive Proxy Statement, any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=a8c5845a8b2ad9636259086a6c2c3961\">www.sec.gov<\/a>. Copies will also be available at no charge at the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;index=11&amp;md5=34499cf845919e466cdbab767f7c4429\">https:\/\/aimimmuno.com\/sec-filings\/<\/a>.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>1<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See <\/i>Former pharma executives sue over firings, Modern Healthcare (June 18, 2018), available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.modernhealthcare.com%2Farticle%2F20180618%2FNEWS%2F180619912%2Fformer-pharma-executives-sue-over-firings&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.modernhealthcare.com%2Farticle%2F20180618%2FNEWS%2F180619912%2Fformer-pharma-executives-sue-over-firings&amp;index=12&amp;md5=2efae570fb0a3eda44172cafc4f35387\">https:\/\/www.modernhealthcare.com\/article\/20180618\/NEWS\/180619912\/former-pharma-executives-sue-over-firings<\/a>.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>2<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See <\/i>Press Release issued by Rockwell Medical on May 24, 2018, available at: https:\/\/www.prnewswire.com\/news-releases\/rockwell-medical-issues-statement-300654699.html.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>3<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See<\/i> Definitive Proxy Statement filed by the Activist Group with the Securities and Exchange Commission (the \u201cSEC\u201d) on November 6, 2024.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>4<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See <\/i>Jorgl v. AIM ImmunoTech Inc. et al., 2022 WL 16543834, at *1 (Del. Ch. Oct. 28, 2022).<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>5<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See <\/i>Jorgl v. AIM ImmunoTech Inc. et al., 2022 WL 16543834, at *1 (Del. Ch. Oct. 28, 2022).<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>6<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See<\/i> Jorgl, 2022 WL 16543834, at *3.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>7<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See<\/i> December 28, 2023, Opinion of the Delaware Court of Chancery: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcourts.delaware.gov%2FOpinions%2FDownload.aspx%3Fid%3D357400&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=https%3A%2F%2Fcourts.delaware.gov%2FOpinions%2FDownload.aspx%3Fid%3D357400&amp;index=13&amp;md5=cf908f33335299914c0caf0d559f7594\">https:\/\/courts.delaware.gov\/Opinions\/Download.aspx?id=357400<\/a> (emphasis added).<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>8<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See id.<\/i> (emphasis added).<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>9<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See id.<\/i> (emphasis added).<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>10<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See id.<\/i> (emphasis added).<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>11<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See id.<\/i> (emphasis added).<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>12<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See<\/i> Definitive Proxy Statement filed by the Activist Group with the SEC on November 6, 2024.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>13<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See <\/i>PS<i \/>Capital Partners\u2019 Testimonials Page available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpscapitalpartners.com%2Ftestimonials%2F&amp;esheet=54159688&amp;newsitemid=20241202183592&amp;lan=en-US&amp;anchor=https%3A%2F%2Fpscapitalpartners.com%2Ftestimonials%2F&amp;index=14&amp;md5=f71f8aa9adfaf18fd34a8222cdd2b242\">https:\/\/pscapitalpartners.com\/testimonials\/<\/a>.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwpadb3 bwalignl bwvertalignt\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><sup>14<\/sup><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><i>See<\/i> The Activist Group Compiled Nomination Notice.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n\u00a0<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241202183592r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20241202183592\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20241202183592\/en\/<\/a><\/span><\/p>\n<p><b>Investor:<br \/>\n<\/b><br \/>JTC Team, LLC<br \/>\n<br \/>Jenene Thomas<br \/>\n<br \/>908-824-0775<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:AIM@jtcir.com\">AIM@jtcir.com<\/a><\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Longacre Square Partners<br \/>\n<br \/>Joe Germani \/ Miller Winston<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:AIM@longacresquare.com\">AIM@longacresquare.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Florida<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Health Pharmaceutical Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board Highlights Activist Group\u2019s Nominees\u2019 Checkered Backgrounds, Skewed Incentives and Lack of Independence Warns AIM Shareholders of Activist Group\u2019s Plan to Reimburse Individuals More Than $5 Million for Failed Litigation Against AIM, in Addition to Any Expenses Incurred in Connection With This Year\u2019s Proxy Contest Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates and Discarding Any Proxy Materials Received from the Activist Group OCALA, Fla.&#8211;(BUSINESS WIRE)&#8211; AIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d) today issued a presentation highlighting why shareholders should NOT elect the four director candidates nominated by a group of activist investors (collectively, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-791455","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board Highlights Activist Group\u2019s Nominees\u2019 Checkered Backgrounds, Skewed Incentives and Lack of Independence Warns AIM Shareholders of Activist Group\u2019s Plan to Reimburse Individuals More Than $5 Million for Failed Litigation Against AIM, in Addition to Any Expenses Incurred in Connection With This Year\u2019s Proxy Contest Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates and Discarding Any Proxy Materials Received from the Activist Group OCALA, Fla.&#8211;(BUSINESS WIRE)&#8211; AIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d) today issued a presentation highlighting why shareholders should NOT elect the four director candidates nominated by a group of activist investors (collectively, &hellip; Continue reading &quot;AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-02T13:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241202183592r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board\",\"datePublished\":\"2024-12-02T13:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/\"},\"wordCount\":2170,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241202183592r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/\",\"name\":\"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241202183592r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2024-12-02T13:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241202183592r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241202183592r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/","og_locale":"en_US","og_type":"article","og_title":"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board - Market Newsdesk","og_description":"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board Highlights Activist Group\u2019s Nominees\u2019 Checkered Backgrounds, Skewed Incentives and Lack of Independence Warns AIM Shareholders of Activist Group\u2019s Plan to Reimburse Individuals More Than $5 Million for Failed Litigation Against AIM, in Addition to Any Expenses Incurred in Connection With This Year\u2019s Proxy Contest Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates and Discarding Any Proxy Materials Received from the Activist Group OCALA, Fla.&#8211;(BUSINESS WIRE)&#8211; AIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d) today issued a presentation highlighting why shareholders should NOT elect the four director candidates nominated by a group of activist investors (collectively, &hellip; Continue reading \"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-02T13:03:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241202183592r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board","datePublished":"2024-12-02T13:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/"},"wordCount":2170,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241202183592r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/","name":"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241202183592r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2024-12-02T13:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241202183592r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241202183592r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group\u2019s Nominees to the Board"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=791455"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791455\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=791455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=791455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=791455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}